HELM INTELLIGENCEABBV
Preparing your analysis.
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Working on your request
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Investors should consider the company's revenue growth alongside its high valuation metrics when making decisions.
AbbVie Inc. has a market capitalization of $455.82B and a current price of $257.09, reflecting a day change of +0.83%. The company reported a revenue growth of 8.57% year-over-year, while EPS has declined by 1.26%. The P/E ratio stands at 108.94, and the dividend yield is 2.56%. AbbVie’s stock has a 52-week range between $190.75 and $267.48.
Some investors point to AbbVie's revenue growth of 8.57% year-over-year as a sign of strong underlying demand for its products. Additionally, the recent success of Atogepant in late-stage studies could expand its market reach and drive future growth.
The high P/E ratio of 108.94 raises concerns about the stock being potentially overpriced, especially given the negative EPS growth of -1.26%. Furthermore, the company's current ratio of 0.67 indicates potential liquidity issues, which could hinder operations.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
AbbVie Inc. has a market capitalization of $455.82B and a current price of $257.09, reflecting a day change of +0.83%. The company reported a revenue growth of 8.57% year-over-year, while EPS has declined by 1.26%. The P/E ratio stands at 108.94, and the dividend yield is 2.56%. AbbVie’s stock has a 52-week range between $190.75 and $267.48.
The high P/E ratio of 108.94 raises concerns about the stock being potentially overpriced, especially given the negative EPS growth of -1.26%. Furthermore, the company's current ratio of 0.67 indicates potential liquidity issues, which could hinder operations.
Some investors point to AbbVie's revenue growth of 8.57% year-over-year as a sign of strong underlying demand for its products. Additionally, the recent success of Atogepant in late-stage studies could expand its market reach and drive future growth.
Some investors point to AbbVie's revenue growth of 8.57% year-over-year as a sign of strong underlying demand for its products. Additionally, the recent success of Atogepant in late-stage studies could expand its market reach and drive future growth. The high P/E ratio of 108.94 raises concerns about the stock being potentially overpriced, especially given the negative EPS growth of -1.26%. Furthermore, the company's current ratio of 0.67 indicates potential liquidity issues, which could hinder operations.
AbbVie Inc. has a market capitalization of $455.82B and a current price of $257.09, reflecting a day change of +0.83%. The company reported a revenue growth of 8.57% year-over-year, while EPS has declined by 1.26%. The P/E ratio stands at 108.94, and the dividend yield is 2.56%. AbbVie’s stock has a 52-week range between $190.75 and $267.48.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for ABBV at helmterminal.dev/analyze/ABBV, updated continuously during US market hours. No signup required.